State Street Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 60,954,967 shares of the biopharmaceutical company’s stock after selling 261,585 shares during the quarter. State Street Corp owned 4.91% of Gilead Sciences worth $9,085,338,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc bought a new stake in Gilead Sciences in the 2nd quarter worth $1,316,606,000. Deutsche Bank AG bought a new stake in Gilead Sciences in the 2nd quarter worth $918,387,000. Jupiter Topco LLC bought a new stake in Gilead Sciences in the 2nd quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at about $398,905,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $170.55, for a total value of $4,775,400.00. Following the completion of the sale, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. This trade represents a 20.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. The trade was a 38.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 237,709 shares of company stock worth $39,799,137. 0.30% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Several brokerages have recently commented on GILD. Argus set a $190.00 price objective on shares of Gilead Sciences in a research note on Thursday, November 12th. Barclays increased their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock an “equal weight” rating in a report on Monday, November 16th. Morgan Stanley raised their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. TD Cowen set a $175.00 price target on Gilead Sciences in a report on Wednesday. Finally, Truist Financial upped their price target on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $171.63.
Read Our Latest Analysis on Gilead Sciences
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $166.33 on Friday. The stock has a market cap of $206.30 billion, a P/E ratio of -52.64 and a beta of 0.35. The firm’s fifty day simple moving average is $157.26 and its 200 day simple moving average is $142.46. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the firm earned $2.47 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.97 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s payout ratio is presently -103.80%.
Gilead Sciences Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
